Protalix BioTherapeutics (PLX) Corporate presentation summary

Commercial portfolio and strategy

• Elfabrio is approved in the U.S., EU and additional markets; Chiesi is the global commercialization partner. Elelyso is approved in 23 markets, with Pfizer and Fundação Oswaldo Cruz as partners.

• Elfabrio’s Fabry market was estimated at ~$2.2B in 2025 and projected to reach ~$3.2B by 2031; management believes it can capture 15%–20% of the global market.

• Every-4-week Elfabrio dosing for stable adults is approved in multiple regions, including the EU and UK; the U.S. FDA-approved regimen remains every 2 weeks. Chiesi paid a $25M regulatory milestone.

• Elelyso generated $11M in Brazil sales in FY2025, with ~25% market share there; potential milestone payments are expected in the mid and long term.

PRX-115 for uncontrolled gout

• Phase 1 data: one 36 mg infusion kept mean plasma uric acid below 6.0 mg/dL for up to 12 weeks; 4 of 6 participants were below 2 mg/dL at week 8.

• Phase 1 was generally well tolerated; related adverse events were mostly mild to moderate and transient. One anaphylactic reaction resolved, with no other serious adverse events reported.

• The Phase 2 RELEASE study is actively enrolling and tests fixed 36 mg doses at 4-, 6- and 8-week intervals, with or without methotrexate, against placebo; top-line results are expected in 2H 2027.

• The primary endpoint is the proportion achieving serum uric acid below 6.0 mg/dL for at least 80% of the time during Month 6; secondary endpoints include safety and immunogenicity.

• ~180,000 U.S. patients are estimated eligible for uricase, while 6,000–8,000 receive Krystexxa; Krystexxa net sales were $1.35B in 2025.

Financial position

• First nine months of 2026 revenue was $75.6M, up $32.0M from $43.6M in the same period of 2025; net income was $26.1M.

• Cash, cash equivalents and short-term deposits totaled $48.5M at September 30, 2026; there was no debt or warrants, and 82.5M common shares were outstanding.